CTOs on the Move

Stealth BioTherapeutics

www.stealthbt.com

 
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stealthbt.com
  • 275 Grove Street Ste. 3-107
    Newton, MA USA 02466
  • Phone: 617.600.6888

Executives

Name Title Contact Details

Funding

Stealth BioTherapeutics raised $100M on 06/18/2018
Stealth BioTherapeutics raised $20M on 04/13/2020
Stealth BioTherapeutics raised $30M on 05/17/2021

Similar Companies

SkinMedica

SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets

IntelligentMDx

IntelligentMDx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemBridge Research Laboratories (CRL)

ChemBridge Research Laboratories (CRL) is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextImage Medical

NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.